SCM
SPRY icon

Silverarc Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Silverarc Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-209,108
Closed -$887K – 91
2022
Q2 		$887K Buy
+209,108
New +$729K 0.27% 57

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Silverarc Capital Management's SPRY Position: Q3 2022 in Review

Silverarc Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2022, closing a stake of 209,108 shares — an estimated $887K sold.

Silverarc Capital Management first reported a position in SPRY in Q2 2022 and held it in 1 quarter. The position peaked at $887K in Q2 2022. 61 funds tracked by Wall St. Rank hold SPRY as of Q3 2022.

  • Silverarc Capital Management reported no remaining ARS Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 209,108 ARS Pharmaceuticals shares in Q3 2022, an estimated $887K.
  • Silverarc Capital Management first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Silverarc Capital Management's ARS Pharmaceuticals position peaked at $887K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2022.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.